VIVOZON PHARMACEUTICAL CO., LTD.
Develops multi-target drugs for pain and central nervous system (CNS) diseases.
082800 | KO
Overview
Corporate Details
- ISIN(s):
- KR7082800004
- LEI:
- Country:
- South Korea
- Address:
- 경기도 화성시 향남읍 제약공단2길 34-40, 화성시
- Website:
- https://www.vivozon.com/
- Sector:
- Manufacturing
Description
VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-05 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2024-02-05 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2024-02-02 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2024-01-31 00:00 |
자기주식처분결과보고서
|
Korean | 16.2 KB | ||
| 2024-01-31 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2024-01-30 00:00 |
주요사항보고서(자기주식처분결정)
|
Korean | 25.4 KB | ||
| 2024-01-22 00:00 |
전환가액의조정(제20회차)
|
Korean | 12.6 KB | ||
| 2023-12-20 00:00 |
전환가액의조정(제20회차)
|
Korean | 12.2 KB | ||
| 2023-12-20 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득(제20회차)
|
Korean | 9.3 KB | ||
| 2023-12-14 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2023-12-01 00:00 |
[기재정정]주요사항보고서(전환사채권발행결정)
|
Korean | 42.2 KB | ||
| 2023-11-22 00:00 |
투자판단관련주요경영사항(어나프라주(오피란제린염산염) 품목허가 신청)
|
Korean | 11.0 KB | ||
| 2023-11-20 00:00 |
전환가액의조정(제20회차)
|
Korean | 12.5 KB | ||
| 2023-11-14 00:00 |
분기보고서 (2023.09)
|
Korean | 1.9 MB | ||
| 2023-11-09 00:00 |
주권매매거래정지해제(액면병합 주권 변경상장)
|
Korean | 4.3 KB |
Automate Your Workflow. Get a real-time feed of all VIVOZON PHARMACEUTICAL CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for VIVOZON PHARMACEUTICAL CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for VIVOZON PHARMACEUTICAL CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
